Development of innovative hyperimmune serums for the prevention and treatment of infectious diseases in animals
نویسندگان
1 Department Biodiversity and Bioresources, al-Farabi Kazakh National University, Almaty, Kazakhstan
2 Scientific and Production Centre
3 Scientific and Production Centre
4 Scientific and Production Centre
5 Scientific and Production Centre
6 Limited Liability Partnership “Kazakh Scientific Research Veterinary Institute” (LLP “KazSRVI”) Almaty, Kazakhstan
7 Scientific and Production Centre
8 Neurox Technology Ltd., Türkiye
doi
10.22124/cjes.2025.9362چکیده
The objective of this study was to produce and evaluate a new hyperimmune serum to prevent and treat infectious diseases in animals. In this study, 20 sheep were subjected to an optimized immunization protocol that included five antigen injections with Freund's complete adjuvant. The results obtained showed that the specific antibody titer produced reached 1:51,200, significantly superior to those obtained by previous studies. After plasma extraction, purification was done by protein A affinity chromatography with an efficiency of 81.6% and purity of 96.8%. The neutralizing activity of the serum produced in vitro was evaluated and found to retain 98.5% of its antiviral activity even at a dilution of 1:128. In the in vivo challenge study, a survival rate of 90% was realized for the group treated with the product, compared to 20% in the control group (p < 0.05). Pharmacokinetic parameters also indicated a half-life of 18.5 days and a Cmax of 245 μg mL-1 for the antibodies. The final product presented endotoxin levels of less than 0.25 EU mL-1 and a satisfactory sterility test, proving its stability at 4 °C within 12 months with 95.2% residual activity. This study demonstrated that the hyperimmune serum produced is a potential and effective therapeutic alternative in the fight against infectious diseases affecting animals.
